The majority of mice immunized with B7 gene modified LEXs did, however, not show long-term survival during our observation period, suggesting that the overexpression of costimulatory molecules alone in LEX-based vaccines may still not be sufficient to inhibit tumor progression. The gene discussed is CD80; the disease is neoplasm.